GCG and cardiovascular disorder: Promising therapeutic approaches specifically targeting ceramides biosynthesis have been reported (18,19), but it is unknown whether ceramides could be modified by therapeutic interventions that are known to reprogram AT and to reduce cardiovascular disease risk, such as GLP-1 analogs (20).